Opaleye Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Opaleye Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.31M	Buy	1,412,656 +11,750	+0.8%	+$30.3K	0.44%	40
2025 Q4	$1.89M	Buy	1,400,906 +1,084,356	+343%	+$1.58M	0.25%	46
2025 Q3	$478K	Sell	316,550 -1,607,750	-84%	-$2.41M	0.07%	40
2025 Q2	$2.23M	Sell	1,924,300 -60,700	-3%	-$80.1K	0.45%	33
2025 Q1	$3.16M	Buy	1,985,000 +217,500	+12%	+$469K	0.7%	29
2024 Q4	$5.36M	Buy	1,767,500 +800,500	+83%	+$2.62M	0.94%	22
2024 Q3	$3.56M	Buy	+967,000	New	+$3.51M	0.59%	30
2024 Q2	–	Sell	-200,000	Closed	-$3.15M	–	60
2024 Q1	$3.15M	Buy	+200,000	New	+$2.75M	0.69%	36
2023 Q1	–	Sell	-167,500	Closed	-$3.37M	–	46
2022 Q4	$3.37M	Buy	+167,500	New	+$3.6M	1.17%	25

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management's ZNTL Position: Q1 2026 in Review

Opaleye Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 0.84% in Q1 2026, buying an estimated $30.3K and bringing the position to 1,412,656 shares worth $3.31M. The position accounts for 0.44% of the portfolio, ranked #40.

Opaleye Management first reported a position in ZNTL in Q4 2022 and has held it in 9 quarters since. The position peaked at $5.36M in Q4 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Opaleye Management held 1,412,656 shares of Zentalis Pharmaceuticals worth $3.31M as of Q1 2026.
Opaleye Management bought 11,750 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $30.3K.
Zentalis Pharmaceuticals made up 0.44% of Opaleye Management's portfolio in Q1 2026, its #40 holding.
Opaleye Management first reported a position in Zentalis Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Opaleye Management's Zentalis Pharmaceuticals position peaked at $5.36M in Q4 2024.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.